• NDA ingediend in Japan voor ergens anders ter wereld
• Nieuw medicijn tegen kanker met een nieuw werkingsmechanisme
• Darinaparsin is in de VS en de EU aangewezen als weesgeneesmiddel voor de behandeling van perifeer T-cellymfoom (PTCL)

 TOKIO–(BUSINESS WIRE)–Solasia Pharma K.K. (TSE: 4597, Hoofdkantoor: Tokyo, Japan, President & CEO: Yoshihiro Arai, hierna “Solasia”) heeft vandaag de indiening aangekondigd van een New Drug Application (NDA) voor zijn nieuwe antikankergeneesmiddel darinaparsin (generieke naam, ontwikkelingscode: SP -02) als behandeling voor recidiverend of refractair perifeer T-cellymfoom aan het Ministry of Health, Labour and Welfare (MHLW). Op basis van positieve resultaten van O&O op darinaparsine, voornamelijk gericht op de resultaten van de Aziatische multinationale fase 2-studie (onderzoeksresultaten vrijgegeven in juni 2020), heeft Solasia een NDA voor het medicijn ingediend bij de regelgevende instantie in Japan, eerder dan waar ook ter wereld.

 Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

• NDA filed in Japan ahead of anywhere else in the world
• New anti-cancer drug with a novel mechanism of action
• Darinaparsin is designated Orphan Drug in the US and EU as a treatment of peripheral T-cell lymphoma (PTCL)

TOKYO–(BUSINESS WIRE)– Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) today announced submission of a New Drug Application (NDA) for its new anti-cancer drug darinaparsin (generic name, development code: SP-02) as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare (MHLW). Based on positive results of R&D on darinaparsin, centered primarily on the results of the Asian Multinational Phase 2 Study (study results released in June 2020), Solasia filed an NDA for the drug with the regulatory authority in Japan ahead of anywhere else in the world.

Solasia expects to obtain regulatory approval in 2022 and to also launch in the same year. If approved and launched, darinaparsin would be the third drug Solasia successfully developed and brought to market since its founding and is expected to contribute to the treatment of PTCL.

Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:

“No standard treatment has been established for relapsed or refractory PTCL as of yet. I firmly believe that darinaparsin, with its novel mechanism of action that differs from those of already approved drugs, will contribute to patients and healthcare providers at clinical sites as a new treatment option for relapsed or refractory PTCL. Since founding, Solasia has conducted R&D on five pipeline drugs. Of the five, we have successfully developed and brought to market two drugs, i.e., began providing them to patients, and today, we submitted an NDA for our first anti-cancer drug. Under our mission to provide patients with ‘Better Medicine for a Brighter Tomorrow’, we will continue aiming to contribute to patients’ treatment and enhanced quality of life. ”

About darinaparsin (SP-02)

Darinaparsin, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. Darinaparsin is believed to exert anticancer effect by inducing cell cycle arrest and apoptosis. Darinaparsin has been granted orphan drug designation in the US and EU.

For more information, please visit at https://solasia.co.jp/en/pipeline/sp-02.html

About Asian Multinational Phase 2 Study

The Asian Multinational Phase 2 Study was a multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in patients with relapsed or refractory PTCL conducted in Japan, Korea, Taiwan, and Hong Kong. (CT.gov Identifier: NCT02653976).

Solasia plans to present the results of the study at an international academic conference to be held in the near future.

About peripheral T-cell lymphoma (PTCL)

Please visit at https://solasia.co.jp/en/pipeline/sp-02.html

About Solasia

Please visit at https://solasia.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005395/en/

Contacts

Solasia Pharma K.K.
Rie Toyoda, Public Relations and Investor Relations,

Tel. +81 3 5843 8049

info@solasia.co.jp